Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02242448
Other study ID # 140158
Secondary ID 14-CC-0158
Status Terminated
Phase
First received
Last updated
Start date July 31, 2014
Est. completion date October 30, 2019

Study information

Verified date October 30, 2019
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- Computed tomography (CT) scanning is a procedure that helps doctors with diagnoses. It uses X-ray radiation to produce an image in three dimensions. Researchers want to study how to get the best quality CT scans using the lowest possible radiation dose.

Objective:

- To determine how to improve CT scanning.

Eligibility:

- Adults 45 years of age and older who have not had a CT scan in the past year and do not have kidney disease.

Design:

- Participants will be screened with a medical history and blood and urine tests.

- Nurses will put an intravenous (IV) line into an arm or hand vein. It will stay in for several hours during the magnetic resonance imaging (MRI) and CT scans. Through this IV, blood will be taken, dye will be injected, and medicine will be given.

- Participants may have a CT scan of the heart, head, chest, abdomen, and/or pelvis. Participants will lie on their back on a table. The table will slide into a donut-shaped machine. An X-ray tube will move around the body, taking pictures.

- Participants may be given a drug called a beta blocker by mouth or through the IV tube.

- Participants heart rate and blood pressure will be monitored.

- Participants may have an MRI scan. The MRI is a large hollow tube. The participant will lie on a table that will be moved into the tube, which contains a magnetic field. When the imaging starts, a thumping sound will be heard. Headphones or earplugs will be provided to muffle the sound.

- Participants will give blood samples.


Description:

In this protocol, computed tomography (CT) imaging performed on healthy volunteers and subjects with disease will be used to test, develop and optimize CT protocols. The results of this optimization will be used to evaluate the performance of new imaging methods and equipment, and to provide essential ground work for research and development for use in future patient CT studies. CT imaging is a noninvasive technology. As appropriate, MRI scans will be used to compare to CT imaging findings to help validate the CT methods.


Recruitment information / eligibility

Status Terminated
Enrollment 109
Est. completion date October 30, 2019
Est. primary completion date October 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years and older
Eligibility - INCLUSION CRITERIA:

- For new or healthy volunteers currently participating in an NIH trial: no CT scan in the last year OR For patients enrolled in a treatment or interventional trial at the NIH: no CT scan in the last 6 months

- Lab Eligibility parameters:

- For CT and MRI contrast enhanced scans:

---eGFR greater than or equal to 60 mL/min/1.73m(2) within 7 days prior to scanning

- For female participants ages 45-60 within 3 days prior to scan (unless post-menopausal or no longer able to bear children, note exemption on initial visit):

- Pregnancy test result(blood or urine): Negative

- Willing to travel to the NIH for follow-up visits.

- Greater than or equal to 45 years old

- Able to understand and sign informed consent

- Stable clinical status

- Volunteer indicates no history of participation in NIH protocols using research radiation in the last 12 months (e.g. PET research scans, NCI Molecular Imaging Center PET scans, etc)

EXCLUSION CRITERIA:

- Prior CT scan in the last 12 months for new volunteers or healthy volunteers enrolled in NIH trials OR Prior CT scan in the last 6 months for patients enrolled in a treatment or interventional trial

- Pregnant women

- Over 500 lbs and/or a body circumference that prevents the study subject from lying flat in the scanner

- Claustrophobia requiring sedation or anesthesia.

- Known or suspected genetic predisposition to cancer

- Any contraindications that the research team identifies from the subject, radiology department CT and/or MRI questionnaires, and/or History and Assessment.

Exclusion for participation for iodinated contrast for CT

(Inclusive of the above exclusion criteria):

- Allergy to iodinated contrast for scans (study subject will be eligible for non-contrast scans)

- Acute renal failure, renal transplant, dialysis and renal failure (clinically diagnosed).<TAB>

- Lactating women

- Patient preference to not undergo intravenous line placement and/or receive iodinated contrast. Contrast administration is optional and participants may still undergo a non-contrast study.

- Use of metformin-containing products less than 24 hours prior To CT contrast administration

- Other contraindications to iodinated contrast media as determined by the research team.

Exclusion for participation for Gadolinium contrast for MRI

(Inclusive of the above exclusion criteria):

- Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.

- Acute renal failure, renal transplant, dialysis and renal failure individuals ( Lab Eligibility parameters and/or clinically diagnosed).<TAB>

- Lactating women

- Patient preference to not undergo intravenous line placement and/or receive gadolinium contrast. Contrast administration is optional and participants may still undergo a non-contrast study.

- Other contraindications to gadolinium contrast media as determined by the research team.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Halliburton S, Arbab-Zadeh A, Dey D, Einstein AJ, Gentry R, George RT, Gerber T, Mahesh M, Weigold WG. State-of-the-art in CT hardware and scan modes for cardiovascular CT. J Cardiovasc Comput Tomogr. 2012 May-Jun;6(3):154-63. doi: 10.1016/j.jcct.2012.04.005. Epub 2012 Apr 7. Review. — View Citation

Mahesh M. Variability in CT protocols. J Am Coll Radiol. 2013 Oct;10(10):805-6. doi: 10.1016/j.jacr.2013.07.005. Epub 2013 Aug 26. — View Citation

Trattner S, Pearson GDN, Chin C, Cody DD, Gupta R, Hess CP, Kalra MK, Kofler JM Jr, Krishnam MS, Einstein AJ. Standardization and optimization of CT protocols to achieve low dose. J Am Coll Radiol. 2014 Mar;11(3):271-278. doi: 10.1016/j.jacr.2013.10.016. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To enhance imaging quality and safety ongoing
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1